~ Delivered Record Annual Revenue with Full-Year Net PEDMARK® Product Sales of $44.6 Million, Representing 50% Year-Over-Year Growth, and Q4 2025 Net Product Sales of $13.8 Million, Representing 75% Growth Over Q4 2024 Net Product Sales ~ ~ Executed on 2025 Clinical Data Strategy to Expand Real-World Validation of PEDMARK® Across New Tumor Types and Patient Populations Through Independent, Institution-Led Research ~ ~ […]
Category: Uncategorized
Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2025 Financial Results on March 24, 2026
RESEARCH TRIANGLE PARK, N.C., March 18, 2026 – Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its full year and fourth quarter 2025 financial results before the opening of the U.S. financial markets on Tuesday, March 24, 2026. Management will host a conference call and webcast that […]
FENNEC PHARMACEUTICALS ANNOUNCES SETTLEMENT AGREEMENT RESOLVING PEDMARK PATENT LITIGATION
Research Triangle Park, NC, March 16, 2026 – Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announces that it has entered into an agreement with Cipla Limited and Cipla USA, Inc. to settle the litigation between them regarding Cipla’s application to FDA for approval to market a generic version of Fennec’s PEDMARK® (sodium thiosulfate […]
FENNEC PHARMACEUTICALS ANNOUNCES CLINICAL RESEARCH COLLABORATION WITH TAMPA GENERAL HOSPITAL CANCER INSTITUTE
– Study is Real-World Evaluation of the Clinical Utility of Sodium Thiosulfate Injection (PEDMARK®) in Reducing the Risk of Ototoxicity in Adolescent and Young Adult (AYA) and Adult Patients with Non-Metastatic Solid Tumors Receiving Cisplatin Chemotherapy – Research Triangle Park, NC, March 4, 2026 — Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, […]
FENNEC PHARMACEUTICALS PRESENTS REAL WORLD DATA SUPPORTING THE integration AND CLINICAL USE OF Pedmark® IN TREATING ADULTS WITH HEAD & nECK CANCERS
– Administration of PEDMARK® Approximately Six Hours After Cisplatin was Shown to Be Safe & Easily Integrated into Care for Adults with Head & Neck Cancers (HNC) – – Early Signals of Hearing Preservation Highlight the Potential of PEDMARK® to Address Cisplatin-Induced Hearing Loss, a Critical Survivorship Gap, Without Compromising Cisplatin’s Established Antitumor Activity – […]
FENNEC PHARMACEUTICALS ANNOUNCES Investigator-SPONSORED TRIAL to be Conducted by CITY OF HOPE IN Metastatic Testicular Germ Cell Tumors
– City of Hope to Evaluate PEDMARK® for Reducing Ototoxicity in Adult Men with Stage II-III Metastatic Testicular Germ Cell Tumors – – Initiation of Study Reflects Growing Clinical Interest in Addressing the Burden of Hearing Loss Among Patients Receiving Cisplatin-Based Chemotherapy – Research Triangle Park, NC, December 9, 2025 – Fennec Pharmaceuticals Inc. (NASDAQ:FENC; […]
FENNEC PHARMACEUTICALS ANNOUNCES POSITIVE TOPLINE RESULTS FROM INVESTIGATOR-INITIATED CLINICAL STUDY OF PEDMARK® IN JAPAN TO REDUCE CISPLATIN-INDUCED HEARING LOSS
– Study, Which Enrolled 27 Patients, Met Primary Endpoint with a Significant Reduction in Hearing Loss in 3-18 Year Old Patients who Received PEDMARK® when Compared with Historically Reported Rates of Hearing Loss in Patients Receiving Cisplatin Alone (16-24% versus 56-63%, Respectively) – – PEDMARK® Showed No Interference with Cisplatin Antitumor Activity as Evidenced by […]
FENNEC PHARMACEUTICALS TO PARTICIPATE IN PIPER SANDLER 37TH ANNUAL HEALTHCARE CONFERENCE
RESEARCH TRIANGLE PARK, N.C., November 25, 2025 – Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 3, 2025 at 1:00 p.m. ET, which will be available via webcast. Webcast Detail: […]
FENNEC PHARMACEUTICALS ANNOUNCES COMPLETION OF FULL DEBT REDEMPTION
Research Triangle Park, NC, November 19, 2025 – Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced it has repurchased and redeemed all of Fennec’s outstanding convertible notes issued to Petrichor Opportunities Fund I LP and Petrichor Opportunities Fund I Intermediate LP using proceeds from the closing of the […]
Read More… from FENNEC PHARMACEUTICALS ANNOUNCES COMPLETION OF FULL DEBT REDEMPTION
FENNEC PHARMACEUTICALS ANNOUNCES CLOSING OF PRIVATE OFFERING OF COMMON SHARES IN CANADA
Research Triangle Park, NC, November 17, 2025 – Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced the closing of its non-brokered offering of its common shares in Canada, at a price of US$7.50 per share, with certain of its existing institutional shareholders, for aggregate gross proceeds of US$5,025,000. […]